Применение ингибиторов фактора некроза опухоли при ревматоидном артрите: место этанерцепта

1. <div><p>Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Amer 2001;27: 269-281</p><p>Pincus T, Callahan LF, Sale WG, et al. Severe functional decline, work disability. And increased mortality in 75 rheumatoid arthritis patients studied over 9 years. Arthritis Rheum /984; 27: 864-872</p><p>Насонов E.JI. Ревматоидный артрит как общемедицинская проблема. Терапевт. Архив 2004; 5: 5-7</p><p>Moreland LW, Russell AS, Paulus HE. Management of rheumatoid arthritis; historical context J Rheumatol 2001; 28:1431-1452</p><p>Cash JM, Klippel JH. Second-line drug therapy for rheumatoid arthritis. New Engl J Med 1994; 330: 1368-1375</p><p>Сигидин Я.А., Лукина Г.В. Ревматоидный артрит. Москва, «АНКО», 2001, 328 стр</p><p>Breedveld FC and Kalden JR. Appropriate and effective management of rheumatoid arthritis Ann. Rheum. Dis, 2004; 63; 627 — 633</p><p>O'Dell JR. Therapeutic strategies for rheumatoid arthritis. New Engl J Med 2004; 350: 2591-2602</p><p>Насонов Е.Л. B.H. Лечение ревматоидного артрита. Клинические рекомендации. Издательство «Алмаз», Москва, 2006, 118 стр</p><p>Насонов Е.Л. Метотрексат. Перспективы применениявмедицине. Издательство«Филоматис», Москва, 2005, 196 стр.</p><p>Насонов Е.Л. Лечение ревматоидного артрита: современное состояние проблемы. РМЖ 2006; 14 (8); 573-577</p><p>Combe В. Early rheumatoid arthritis: strategies for prevention and management. Besr Pract Res Clin Rheumatol 21: 27-42</p><p>Cush J.J Early rheumatoid arthritis - Is there a window of opportunity? J Rheumatol 2007; 34: Suppl 80: 1-7</p><p>Mitchell KL, Pisetsky DS. Early rheumatoid arthritis. CurrOpin Rheumatol 2007; 19: 278-283</p><p>Brown AK, Quin MA, Karim Z, el al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatiic drug-induced remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006; 54: 3761-3673</p><p>Ferinstein GS. Evolving concept of rheumatoid arthritis. Nature 2003; 423:356-360</p><p>Beayert R; Fiers W. Tumor necrosis factor and lymphotoxin. In: Mire-Sluis AR, Thorpe R., editors. Cytokines. 1st ed. London: Academic Pr; 1998. pp. 235-60</p><p>Zhang, G. Tumor necrosis factorfamily ligand-receptor binding. CurrOpin Struct Biol 2004; 14:154</p><p>Feldman М., Brennan F., Maini R.N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 1996; 14:397-440</p><p>Насонов EJl. Фармакотерапия ревматоидного артрита в эру генно-инженерных биологических препаратов. Терапевтический Архив , 2007, 5, 5-8</p><p>Насонов E.J1. Фармакотерапия ревматоидного артрита — взгляд в 21 век. Клин, медицина 2005; 6:8-12</p><p>Насонов ЕЛ. Лечение ревматоидного артрита: современное состояние проблемы. РМЖ 2006; 14 (8); 573-577</p><p>KuekA, Hazleman BL, OstorAJK. Immune-mediated inflammatory diseases (IMlDs) and biologic therapy: a medical revolution. Postgrad Med J 2007; 83: 251269</p><p>Насонов Е.Л. Фактор некроза опухоли-а — новая мишень для противовоспалительной терапии ревматоидного артрита. Клин. Фармакол. Терапия 2001;1:64-70</p><p>Насонов Е.Л. Перспективы фармакотерапии воспалительных ревматических заболеваний: моноклональные антитела к фактору некроза опухоли. РМЖ, 2001, 9, 7-9</p><p>Lorenz Н-М, Kalden JR. Perspectives for TNF- a-targeting therapies. Arthritis Research 2002; 4 (Suppl. 3):S17-S24</p><p>Kalden JR. Emerging role of anti-tumor necrosis factor therapy in rheumatic disease. Arthritis Res 2002;4 (Suppl. 2): S34-S40</p><p>Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993;151:1548-61</p><p>Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Phannacol Therapeut 2008; 117:244-279</p><p>Dhillon S, Lyseng-Williamson KA, Scott LJ. Etanercept. A review of its use in the management of rheumatoid arthritis. Drugs 2007; 67:1211-1241</p><p>Ulfgren AK, Andersson U, Engstrom M, et al. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 2000; 43: 2391-2396</p><p>Cartina Al, Lampa J, Ernestam S, et al. Anti tumor necrosis factor (TNF)-a therapy (etanercept) down regulates serum matrix metalloproteinase (MMP)-3 and MMP-l in rheumatoid arthritis. Rheumatol. 2002;41:484-9</p><p>Verschueren PC, Markusse H, Smeets TJM, et al. Reduced cellularity and expression of adhesion molecules and cytokines after treatment with soluble human recombinant TNF receptor (p75) in RA patients [abstract]. Arthritis Rheum. 1999;42 (Suppl):S197, 762</p><p>Schotte H, Schlutter B, Willeke P, et al, Longterm treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology 2004; 43: 960964</p><p>Berg L, Lampa J, van Vollenhoven R, et at. Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFa receptors. Ann Rheum Dis. 2001;60:133-9</p><p>MorelandLW, BucyRP, Weinblatt ME, etal. Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol. 2002;103:13-21</p><p>Korth-Bradley JM, Rubin AS, Hanna RK, et al. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother. 2000;34:161-4</p><p>Zhou H, Mayer PR, Wajdula J, et al. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. J Clin Pharmacol 2004: 44: 1235-1243</p><p>Zhou H, Parks V, Pa tat A, et al. Absence of a clinically relevant interaction between etanercept and digoxin. J Clin Pharmacol 2004; 44: 1244-1251</p><p>Zhou H, Patat A, Parks V, et al. Absence of phatma- cokinetic interaction between etanercept and warfarin. J Clin Pharmacol 2004; 44: 1244-1251</p><p>Moreland LW, Margolies G, Heck LW et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996; 23: 1849-1855</p><p>Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumour necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337:141-47</p><p>Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-486</p><p>Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptorfc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253-9</p><p>Kremer JM, Weinblatt ME, Bankhurst AD et al. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis, continued observation. Arthritis Rheum 2003; 48: 1493-1499</p><p>Moreland LW, Cohen SB, Baumgartner SW, et al. Long term safety and efficact of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001; 28: 1238-1244</p><p>Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675-81</p><p>van der Heijde D, Klareskog L, Rodrigiez-Valvelde V, et al. Comparison of etanercept and metoptrexate, alone and combined, in the treatment of rheumatoid arthritis. Two-year clinical and radiographic results from the TEMPO study, a doble-blind, randomized trial. Arthritis Rheum 2006; 54: 1063-1074</p><p>van der Heijde D, Klareskog L, Landewe R, et a. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56:3928-3939</p><p>Landewe R, van der Heijde D, Klareskog L, et al. Disconnect between inflammation andjoint destruction after treatment with etanercept and methotrexate with radiographic and patients ourcomes. Arthritis Rheum 2006; 54:3119-3125</p><p>Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalisis of data from ATTRACT study. Arthritis Rheum 2005; 52:1020-1030</p><p>van der Heijde D, Burmester G, Melo-Gomes J. et al. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy, Ann Rheum Dis 2008; 67: 182-188</p><p>Kameda H, Ueki Y, Saito K, et al. The comparison of ejfecacy and safety between etanercept (ETN) plus methotrexate (MT) combonation therapy and ETN monotherapy in MTX-refractory Japanese patients with rheumatoid arthritis; 24-week results frpm JESMR study. Ann Rheum Dis 2008; 67 (Suppl II): 184</p><p>Klareskog L, Gaubitz M, Rodriguez-Valverde V, et al. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease modifying antirheumatic drugs. Ann Rheum Dis 2006; 65: 1578-1584</p><p>Wolfe F, Hawley DJ, Xathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive patients. J Rheumatol 1990; 17: 994-1002</p><p>van Riel PLC, TaggatAJ, Sany J, et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 2006; 65: 14781483</p><p>van Riel PLC, Freundlich B, Mac Peek D, et al. Patient-reported outcome in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. Ann Rheum Dis 2008; 67: 1104-1110</p><p>Насонов Е.Л., Насонова B.A. Рациональная фармакотерапия ревматических болезней. Издательство «Литтера», Москва. 2003, 506 стр</p><p>Combe В, Codreanu С, Fiocco U, et al. Etanercept and sulfasalazine, alone and combaned, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis 2006; 65: 1357-1362</p><p>O'Dell JR. Petersen K, Leff R. et al. Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis. J Rheumatol 2006; 33:213-218</p><p>Finckh A, Dehter S, Gabay С et al. The effectiveness of leflunomide as co-therapy of TNF inhibitors in rheumatoid arthritis. A population based study. Ann Rheum Dis 2008; January 29 on line</p><p>Ikeda K, Cox S, Emery P. Biological therapy in early arthritis - overtreatment or the way to go? Arthritis Res Therapy 2007; 9:211</p><p>Machold KP, Nell VPK, Stamm ТА, Smolen JS. Traditional DMARD therapy: is it sufficient: Arthritis Res Ther 2006:8:21 on lone</p><p>Bathon JM, Martin RW, Fleischmann RM. et al. Comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000:343:1586-93</p><p>Genovese MC, Bathon JM, Martin RW et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two —year radiographic and clinical outcome. Arthritis Rheum 2002; 46; 14431450</p><p>Genovese MC, Bathon JM, Fleishmann RM, et al. Long term safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol 2005; 32: 1223-1242</p><p>Weinblatt ME, Genovese MC, Moreland LW, et al. Efficacy and safety of over 9 years of etanercept (Enbrel) therapy in North American patients with early and long-standing rheumatoid arthritis. Amer Coll Rheum. Annual Sci Meet 2006 Nov 11-15; Washington DC (abst)</p><p>Baumgartner SW, Fleischmann RM, Moreland LW, et al. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent oncet versus established disease improvement in disability. J Rheumatol 2004; 31: 1532-1557</p><p>Emery’ P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. Lancet 2008; July 16, on line</p><p>Moots R, Kekow J, Sato R, et al. Assessment of early treatment with combination of etanercept and methotrexate on functional status among patients with active rheumatoid arthritis: the COMET trial. Ann Rheum Dis 2008; 67 (Suppl II): 188</p><p>Breedveld F, Emery P, Ferraccioli G, et al. Clinical response and remission at 12, 24, and 52 weeks with the combination of etanercept and methotrexate in the treatment of active rheumatoid arthritis in the COMET trial. Ann Rheum Dis 2008; 67 (Suppl II): 320</p><p>Anis A, Zhang W, Emery P. et al. Work-related outcome in early active rheumatoid arthritis: results from the COMET trial. Ann Rheum Dis 2008; 67 (Suppl II): 79</p><p>Tarkeltaub R, Esdaile J, Decary F, Tannenbaum H. A clinical study of older age rheumatoid arthritis with comparison to younger onset group. J Rheumatol 1983; 10: 418-424</p><p>Kaipiainen-Seppanen O, Aho K, Isomaki H, Laakso M. Shift in the incidence of rheumatoid arthritis toward eldery patients in Finland during 1975-1990. Clin Exp Rheumatol 1996; 214:537-542</p><p>Fleishman RM. Baumgartner SIV, Tindall EA, et al. Response to etanercept (Enbrel) in eldery patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol 2003; 30: 691-696</p><p>Bathon JM. Fleischmann RM, van der Heijde DM, et al. Safety and efficacy of etanercept treatment in eldery subjects with rheumatoid arthritis. J Rheumatol 2006; 33: 234-243</p><p>Bakdine C, Delle Sedie A, Bombardieri S. From clinical trials to the bedside: how can we treat patients with rheumatoid arthritis and concurrent morbidities who are generally excluded from randomized controlled clinical trials: Clin Exp Rheumatol 2005; 23: 893-904</p><p>Weisman MH, Paulus HE, Burch FX, et al. A placebo-controlled, randomized, double-blind study evaluating the safety of etanercept in patients with rheumatoid arthritis and concominant comorbid diseases. Rheumatology 2007; 46: 1122-1125</p><p>Baumgatner SW, Fleishman RM, Moreland LW et al. Etanercept (Enbrel in patients with rheumatoid arthritis with early onset versus established disease: improvement in disability. J Rheumat 2004; 31: 1532-1537</p><p>Keystone E, Freundlich B, Schijf M, et al. Patients with moderate rheumatoid arthritis achive better disease activity states with etanercept treatment than patients with severe rheumatoid arthritis. Ann Rheum Dis 2008; 67(Suppl II): 186</p><p>Klareskog L, Moreland LW, Cohen SB, et al. Safety and efficacy of over 10 years of continuous etanercept therapy in patients with rheumatoid arthritis in North America and Europe. Ann Rheum Dis 2008; 67 (Suppl II): 175</p><p>Keystone EC, Schijf MH, Kremer JM, et al. Once- weekly administration of 50mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;50:353-63</p><p>Weinblatt ME, Schijf MH, Ruderman EM, et al. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a sub- optimal response to etanercept 50 mg once a week. Arthritis Rheum 2008; 58: 1921-1930</p><p>Ariza-Ariza R, Navarro-Sarabia F, Hemandez-Cruz B, et al. Dose escalation of the anti- TNF-a agents in patients with rheumatoid arthritis. A systemic review. Rheumatology 2006</p><p>Kavanaugh A, Klareskog L, van der Heijde D, et al. Improvement in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate. Ann Rheum Dis 5 June 2008. on line</p><p>Bliddal H, Terslev L, Qvistgaard E, et al. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticoids in patients with rheumatoid arthritis. Scand J Rheumatol 2006; 35: 341-345</p><p>Roux CH, Brocq O, Valerio L, et al. Etanercept versus glucocorticoids intra-articular (IA) injections in rheumatoid arthritis (RA): a randomizrd double blind study. Ann Rheum Dis 2008; 67: (Suppl II):329</p><p>Villeneuve E, Haraoui B. Switching between TNF-a inhibitors in the treatment of rheumatoid arthritis. Int J Adv Rheumatol 2006; 4: 2-8</p><p>van Vollenhoven RF. Swithing between anti-tumor necrosis factors: tiying to get a handle on a complex issue. Ann Rheum Dis 2007; 66: 849-851</p><p>Lutt JR, DeodharA. Rheumatoid arthritis. Strategies in the management of patients showing an Inadequate response to TNFa antagonist. Drug 2008; 68: 591606</p><p>Iannone F, Trotta F, Montecucco C, etal. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effect. Ann Rheum Dis 2007; 66:249-252</p><p>Cohen G, Courvoiser N, Cohen JD, et al. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid ailhritis. Clin Exp Rheumatol 2005; 23: 795-800</p><p>Di Poi E, Perrin A, Morassi MP, et al. Switching to etanercept in patients with rheumatoid arthritis with no i-esponse to infliximab. Clin Exp Rheumatol 2007; 25: 85-87</p><p>Brocq O, Plubel Y, Breuil V, et al. Etanercept- infliximab swithing in rheumatoid arthritis: 14 out of 131 patients treated with ant-TNFalpha. Presse Med 2002; 62: 1836-1839</p><p>Gomez-Puerto JA, Sanmartin R, Rodriguez-Cros JR, et al. Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy. Ann Rheum Dis 2004; 63: 896</p><p>Haraoui B, Keystone EC, Thorne JC, et al. Clinical outcome of patients with rheumatoid arthritis after swithing from infliximab to etanercept. J Rheumatol 2004; 31:2356-2359</p><p>Cantini F, Niccoli L, Porciello G, et al. Switching from ingliximab or adalimumab to etanercept 500 mg/once weekly in resistant or intollerant patients with rheumatoid arthritis. Arthritis Rheum 2005; 52 (Suppl 9): S384 (abst)</p><p>Buch MH, Bingham SJ. Bejarano V, et al. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switching to etanercept. Arthritis Rheum 2007; 57: 448-453</p><p>Koike T. Harigai M, Inokuma S, et al. Safety and effectiveness of switching from infliximab to etaner- cept in patients with rheumatoid arthritis: results from a large Japanese post marketing surveillance. Ann Rheum Dis 2008; 67: (Suppl II): 181</p><p>Furst DE, Gaylis N, Bray V, et al. Open-labet, pilot protocol of patients with rheumatoid arthritis who swith to infliximab after an incomplerte response to etanercept: the opposite study. Ann Rheum Dis 2007; 66: 893-899</p><p>Bombardieri S, Ruiz AA, Fardellone P, et al. Effectiveness odadalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 2007</p><p>Finckh A, Ciurea A, Brulhart L, et al. В cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to antitumor necrosis factor agents. Arthritis Rheum 2007; 56:1417-1423</p><p>Finckh A, Ciurea A, Brulhart L, et al. H'bich subgroup of rheumatoid arthritis patients benefit most from switching tp Rituximab versus alternative anti-TNF agents after previous failure to anti-TNF agents?Ann Rheum Dis 2008; 67(Suppl II):</p><p>Cohen SB, Emery P, Greenwald MW, etal. Rituximab for theumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 27932806</p><p>Rheumatoid arthritis — adalimumab, etanercept and infliximab (sequential use), http;//www.nice.org.uk/ guidance/index</p><p>Blank N, Max R, Briem S, et al. Combination therapy with Rituximab and etanercept fpr patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67 (Suppl II): 188</p><p>Breedveld PC, Kim D, Agarwal S, et al. Safety of TNF inhibition in rheumatoid arthritis patients previously treated with rituximab. Ann Rheum Dis 2006; 65 (Suppl I): TH0206</p><p>Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritid who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50: 1412-1419 108a. Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomized clinical trial. Ann Rheum Dis 2007; 66: 228-234</p><p>Cohen SB, Cohen MD, Cush JJ, et al. Unresolved issue in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence. J Rheumatol 2008 35 (Suppl 81): 1-30</p><p>De Vries N, Так PP. The response to anti-TNF alpha treatment: gene regulation at the bedside. Rheumatology (Oxford) 2005; 44: 705-707</p><p>Hyrich KL, Watson KD, SilmanAJ, etal. Predictorsof response to anti- TNF-a therapy among patients with rheumatoid arihritis: results from the British Society for Rheumatology Biologies Register. Rheumatology 2006;</p><p>Plenge RM, Criswell LA. Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenge and future directions. CurrOpin Rheumatol 2008; 20: 145-152</p><p>Baseggio L, Bartholin L, Chantome A, et al. Allele specific binding to the -308 single nucleotide polymorphism site in the tumor necrosis factor-alpha promoter. Eur J Immunogenet 2004; 31:15-19</p><p>Bouma G, Crusius JB, Oudkerk Pool M, et al. Secretion of tumor necrosis factor alpha and lympho- toxin alpha in relation to polymorphism in the TNF genes and HLA-DR alleles: relevance for inflammatory bowel disease. Scand J Immunol 1996; 43: 456463</p><p>Louis E, Franchimont D, Piron A, et al. Tumor necrosis factor (TNF) gene polymorphism influence TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culturw in healthy humans. Clin Exp Imunol 1998; 113: 411-406</p><p>Guis S, Balanraud N, Bouvenot J, et al. Influence of -308 A/G polymorphism in the tumor necrosis factor a gene on etanercept treatment in rheumatoid arthritis. Arthritis Care Res 2007; 57: 1426-1430</p><p>Seitz M, Wirthmuller U, Moller B, Villinger PM. The -308 tumor necrosis factor-a polymorphism predict therapeutic response to TNF-a blockers in rheumatoid arihritis and spondiloaarthritis patients. Rheumatology 2007; 46: 93-9</p><p>Padyukov L, Lampa J, Heimburger M, et al. Genetic markers of the efficacy of tumor necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003; 62: 526-529</p><p>Criswell LA, Lum RF, Turner KN, etal. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arihritis with methotrexate and etanercept. Arthritis Rheum 2004; 50:2750-2756</p><p>Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of Fey Rif I (CD16) alters receptor function and predisposes to autoimmune diseases. J Clin Invest 1997; 100: 1059-1070</p><p>Kastbom A, Bratt J, Emestam S, et al. Fey receptor type III genotype and response to tumor necrosis factor-a-blocking agent in patients with rheumatoid arthritis. Arihritis Rheum 2007;56: 448-452</p><p>Koczan, Drynda S, Hecker M, et al. Molecular discrimination of responder and nonresponder to anti- TNFalpha in rheumatoid arihritis by etanercept. Arth Res Ther 2008; 10.R50 online</p><p>Насонов EJl. Новые возможности фармакотерапии ревматических болезней — ингибирование интерлейкина 6. Клин Фармакол Терапия 2008; 1: 60-67 123а. Potter С, Hyrich KL, Tracey A, et al. Association of RF and anti-ССР positivity, but not carriage of shared epitope or PTPN22 sussceptibility variants, with anti- TNFresponse in RA. Ann Rheum Dis 2008, Mae 28, on line</p><p>Chen Y-F, Jobanputra P, Barton P, et al. A systemic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment ofrheumatoid arthritis in adults and economic of their cost-effectiveness. Helth Technol Assess 2006; 10(42)</p><p>CartlehnerG, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologies for the treatment of rheumatoid arihritis: a systemic review and metaanalysis. J Rheumatol 2006; 33: 2398-2408</p><p>Alonso-Ruiz A, Pijoan Jl, Ansuategui E et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systemic review and metaanalysis of efficacy and safety. BMC musculoskeletal disorders 2008; 9:52</p><p>Donahue KE et at. Systemic review: comparative effectiveness and harm of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148: 124-131</p><p>Nixon R, Bansback N, Brennan A. The efficacy of inhibiting tumor necrosis factor alpha and interleukin 1 in patients with rheumatoid arihritis: a meta-analysis and adjusted indferect comparisons. Rheumatology 2007, on line</p><p>Zink A, StrangfeldA, Schneider M, etal. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observation cohort study. Arihritis Rheum 2006; 54:3399-3407</p><p>Hyrich KM, Symmons DPM, Watson KD, et al. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis. Results from the BSBR. Arthritis Rheum 2006; 54: 1786-1794</p><p>Krisatensen LE, Saxne T, Geborek P. The LUND EX. a new index of drug efficacy in clinical practice. Results of a five-years observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in Southern Sweden. Arthritis Rheum 2006; 54: 600-606</p><p>Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007; 66 (Suppl UI):iii2-iii22</p><p>Stone JH. Tumor necrosis factor-alpha inhibitors: an overview of adverse effects. Up To Date 2008, May 31, version 16.2</p><p>AsklingJ, Dixon W. The safety of anti-tumor necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008; 20: 138-144</p><p>Solomon DH, Lunt M, Schneeweiss S. The risk of infection associated with tumor necrosis factor a antagonist. Making sence of epidemiologic evidence. Arthritis Rheum 2008; 58: 919-928</p><p>Козлов PC, Якушин СБ, Насонов EJI. Инфекционные осложнения терапии блокато- рами фактора некроза опухоли: предупрежден — значит вооружен. Клиническая Микробиология и антимикробная химиотерапия, 2006, 8:314-324</p><p>Kim НА, Yoo CD, Baek HJ, et at. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol 1998; 16:9-13</p><p>Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46:2287-2293</p><p>Flynn, JL, Goldstein, MM, Chan, J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995; 2:561</p><p>Benini, J, Ehlers, EM, Ehlers, S. Different types of pulmonary granuloma necrosis in immunocompetent vi. TNFRp55-gene-deficient mice aerogenically infected with highly virulent Mycobacterium avium. J Pathol 1999; 189:127</p><p>Allendoerfer, R, Deepe, GS Jr. Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J Immunol 1998; 160:6072</p><p>Garcia, I, Miyazaki, Y, Marchal, G, et al. High sensitivity of transgenic mice expressing soluble TNFR1 fusion protein to mycobacterial infections: synergistic action of TNF and IFN-gamma in the differentiation of protective granulomas. Eur J Immunol 1997; 27:3182</p><p>Bopst, M, Garcia, I, Guler, R, etal. Differential effects of TNF and LTalpha in the host defense against M. bovis BCG. Eur J Immunol 2001; 31:1935</p><p>Kindler, V, Sappino, AP, Grau, GE, et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56:731</p><p>Kroesen, S, Widmer, AF, Tyndall, A, Hosier, P. Serious bacterial infections in patients with rheumatoid arihritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003; 42:617</p><p>Crum, NF, Lederman, ER, Wallace, MR. Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 2005; 84:291</p><p>Gomez-Reino, JJ, Carmona, L, Valverde, VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active- surveillance report. Arihritis Rheum 2003; 48:2122</p><p>Listing, J, Strangfeld, A, Kary, S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52:3403</p><p>Curtis, JR, Patkar, N, Xie, A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007; 56:1125</p><p>Curtis, JR, Xi, J, Patkar, N, et al. Drug-specific and time-dependent risks of bacteria! infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007; 56:4226</p><p>Dixon, WG, Watson, K, Lunt, M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necmsis factor therapy: results from the British Society for Rheumatology Biologies Register. Arthritis Rheum 2006; 54:2368</p><p>Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalisation for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006; 54: 628-634</p><p>Schneeweiss S, Setoguchi S, Weinblatt ME, et at. Antitumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007; 56:1754-1764</p><p>Askling J, Fored CM, Brandt L, et al. Time- dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007; 66:13391344</p><p>Dixon WG, Symmons DP, Lunt M, et al. Serious infection following antitumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007; 56:2896-2904</p><p>Keane, J, Gershon, S, Wise, RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098</p><p>Brassard, P, Kezpuh, A, Suissa, S. Antirheumatic Drugs and the Risk of Tuberculosis. Clin Infect Dis 2006; 43:717</p><p>Wallis, RS, Broder, MS, Wong, JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004:38:1261</p><p>Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372-9</p><p>Dixon WG, Hyrich KL, Watson KD, et al. Drug- specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSP biologies register (BSRBR). Ann Rheum Dis 2008; 67: (Supp II) :178</p><p>Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005;52(7):1986-92</p><p>Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52(6): 1766-72</p><p>Fonseca JE, Canhao H, Silva C. [Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: The Portuguese experience]. Acta Reumatol Port 2006;31(3):247-53</p><p>Tubach F, Salmon D, Ravaud P, et at. The risk of tuberculosis with anti-TNF is higher with monoclonal antibodies than with the soluble receptor. Results of the French 3-year prospective ratio observation. Ann Rheum Dis 2008; 67: (Suppl II): 52</p><p>Nestorov, I. Clinical pharmacokinetics of TNF antagonists: how do they differ?. Semin Arthritis Rheum 2005; 34:12</p><p>Saliu, OY. Safer, C, Stein, DS, etal. Tumor-necrosis- factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006; 194:486</p><p>Guidotti, LG, Isliikawa, T, Hobbs, MV, et al. Intracellular inactivation of the hepatitis В virus by cytotoxic T lymphocytes. Immunity 1996; 4:25</p><p>Guidotti, LG, Ando, K. Hobbs, MV, et al. Cytotoxic T lymphocytes inhibit hepatitis В virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA 1994; 91:3764</p><p>Nelson, DR, him, HL, Marousis, CG, etal. Activation of tumor necrosis factor-alpha system in chronic hepatitis С virus infection. Dig Dis Sci 1997; 42:2487</p><p>Ferri C, Ferraccioli G, Feirari D, et al. Safety of anti-tumor necrosis factor-a therapy in patients with rheumatoid arthritis and chronic hepatitis С virus infection. J Rheumatol 2008, Aug 1. on line</p><p>Marotte H, Fontanges E, Bailly F, et al. Etanercept treatment for three month is safe in patients with rheumatologic manifestations associated with hepatitis С virus. Rheumatology 2007; 46: 97-99</p><p>Mohan, N, Edwards, ET, Cupps, TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44:2862</p><p>Насонов ЕЛ., Самсонов М.Ю. Новые аспекты патогенеза сердечной недостаточности: роль фактора некроза опухоли Сердечная недостаточность, 2000: 1(4): 139-143</p><p>Mann, D, Me Murray, J, Packer, М, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation 2004; 109:1594</p><p>Anker, SD, Coats, AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002; 86:123</p><p>Gabriel, SE. Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis?. Arthritis Rheum 2008; 58:637</p><p>Насонов ЕЛ. Проблема атеротромбоза в ревматологии. Вестник РАМН,2003; 7, 6-10</p><p>Насонов Е.Л. Ревматоидный артрит — модель атеротромбоза РМЖ 2005; 13:509-512</p><p>Jacobsson LTH, TuressonC,CulfeA,etal. Treatment with tumor necrosis factor blockers is associated with a tower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1213-1228</p><p>Jacobsson LTN, Turesson C, Nilsson J-A, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 670-675</p><p>Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor a therapy. Results from the British Society for Rheumatology Biologies Register. Arthritis Rheum 2007; 56: 2905-2912</p><p>Furst DE, Sokolove J, Greenberg J, et al. Risk of ele&gt;ated liver enzyme (LFTS) with THF inhibitors in rheumatoid arthritis: analysis in 6861 patients with 22552 visits. Ann Rheum Dis 2008; 67:52</p><p>Haraoui B, Keystone E. Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. CurrOpin Rheumatol 2006; 18: 96-100</p><p>Mongey A-В, Hess EV. Drug insight: autoimmune effects of medications - whates new? Nat Clin Pract Rheumatol 2008; 4:136-144'</p><p>De Rycke L el al. (2005) Infliximab, but not etanercept, induced IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 52: 2192—2201</p><p>Eriksson С et al. (2005) Autoantibody formation in patients with rheumatoid arthritis treated with anti- TNF alpha. Ann Rheum Dis 64: 403-407</p><p>Bacquet-Deschryver H, Jouen F, Quillard M, et al. Impact of three anti-TNFa biologies on exising and emergent autoimmunity in rheumatoid arthritis and spondiloarthropthy patients J Clin Rheumatol 2008, on line</p><p>Benucci M, Saviola G, Baiardi P, et al. Anti- nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFa blocking agents in rheumatoid arthritis. Clin Rheumatol 2008; 27: 91-95</p><p>Gonnet-Gracia C, Barnetche T, Richez C, et al.Antinuclear antibodies, anti-DNA and C4 complement evaluation in rheumatoid arthritisd and ankylosing spondylitis treated with TNF-a blockers. Clin Exsp Rheumatol 2008; 26: 401-407</p><p>Shakoor N et al. (2002) Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359:579-580</p><p>Georgescu, L, Quinn, GC, Schwartzman, S, Paget,</p><p>Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 1997; 26:794</p><p>Gridley, G, McLaughlin, JK, Ekbom, A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85:307</p><p>Ebeo, CT, Girish, MR, Byrd, RP. etal. Methotrexate- induced pulmonary lymphoma. Chest 2003; 123:2150</p><p>Seroguchi S, Solomon DH, Weinblatt ME, et al. Tumor necrosis factor a antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:2757-2764</p><p>Askling J, Fored CM. Baecklund E, et al. Haemotopoietic malignances in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumor necrosis factot antagonists. Ann Rheum Dis 2005; 64:1414-1420</p><p>Wolfe, F, Michaud, K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007; 56:1433</p><p>Wolfe F, Michaud K. Lymphoma in rheumatoid arihritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18572 patients. Arthritis Rheum 2004; 40: 1740-1751</p><p>Geborek, P, Bladstrom, A, Turesson, C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005; 64:699</p><p>Wolfe, W, Michaud, K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. Arthritis Rheum 2007; 56:2886</p><p>Stone, JH, Holbrook, JT, Marriott, MA, et al. Solid malignancies among patients in the Wegener’s Granulomatosis Etanercept Trial. Arthritis Rheum 2006; 54:1608</p></div><br />